Publication & Citation Trends
Most Cited Works
Publications
192 total
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
Cited by 228
OpenAlex
Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage III colon cancer: a post hoc analysis of the CALGB/SWOG 80702 phase III study (Alliance)☆ PDF
Cited by 118
OpenAlex
Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma PDF
Cited by 134
OpenAlex
Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study PDF
Cited by 274
OpenAlex
Research Topics
Colorectal Cancer Treatments and Studies
(103)
Cancer Immunotherapy and Biomarkers
(39)
Gastric Cancer Management and Outcomes
(36)
Genetic factors in colorectal cancer
(29)
Colorectal Cancer Surgical Treatments
(27)
Frequent Co-Authors
Affiliations
Novartis (Switzerland)
The University of Texas MD Anderson Cancer Center
Bayer (United States)
Bristol-Myers Squibb (Germany)
Daiichi Sankyo (Germany)